Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Monopar Therapeutics Director's Dealing 2021

Jun 2, 2021

32883_dirs_2021-06-02_6a26922a-d891-43de-a9e7-fbc3514e63e7.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3/A — Form 3/A

Issuer: Monopar Therapeutics (MNPR)
CIK: 0001645469
Period of Report: 2021-06-01

Reporting Person: Cittadine Andrew (N/A)